Abstract
Although autologous stem cell transplantation (ASCT) has gained some popularity as a treatment option in patients with chronic lymphocytic leukaemia (CLL), limited multicentre data are available on the feasibility and efficacy of this approach. Between January 1995 and June 2005, 72 patients with CLL received ASCT in five Finnish centres. There were 45 men and 27 women with a median age of 57 years (38–69). The median time from diagnosis to ASCT was 32 months (6–181) and the median number of prior regimens 1 (1–4). All patients received blood stem cell grafts and CD34+ selection had been performed in 44 patients (61%). The most common high-dose regimen was a total body irradiation plus cyclophosphamide (38 patients, 53%). No early treatment-related deaths were observed. With a median follow-up of 28 months from ASCT, a relapse or progression has been observed in 27 patients (37%). The projected progression-free survival is 48 months (confidence interval (CI) 30–66). The projected median overall survival is 95 months (CI 74–101) from ASCT and is not influenced by graft selection or conditioning regimen used. Autologous stem cell transplantation is a feasible treatment option for CLL. Randomized trials against alternative treatments are needed to assess the impact of ASCT on the clinical course of CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Hamblin TJ, Davis Z, Gardiner A, Oschier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.
Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy in younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891.
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.
Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R et al. Fludarabine combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031.
Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4009–4012.
Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078.
Dreger P, von Neuhoff N, Kuse R, Sonnen R, Glass B, Uharek L et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance of cure? Br J Cancer 1998; 77: 2201–2207.
Dreger P, Montserrat E . Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985–992.
Jabbour E, Keating MJ, Champlin RE, Khouri IF . Stem cell transplantation for chronic lymphocytic leukaemia: should not more patients get a transplant. Bone Marrow Transplant 2004; 34: 289–297.
Paneesha S, Milligan DW . Stem cell transplantation for chronic lymphocytic leukaemia. Br J Haematol 2005; 128: 145–152.
Rabinowe SN, Soiffer RJ, Gribben J, Daley H, Freedman AS, Daley J et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376.
Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.
Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049–2053.
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.
Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD et al. Results of MRC pilot study show autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Itälä M, Pelliniemi TT, Rajamäki A, Remes K . Autologous stem cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647–651.
Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemia Working Party (CLWP). Br J Haematol 2000; 108: 595–601.
Tournhilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem mobilization in B-cell chronic lymphocytic leukaemia. Blood 2004; 103: 363–365.
Altes A, Sierra J, Esteve J, Martin-Henan G, Marin P, Sureda A et al. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 2002; 30: 824–830.
Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: a risk-matched analysis on the VH gene mutational status. Blood 2004; 103: 2850–2858.
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adopted therapy. J Clin Oncol 2006; 24: 437–443.
Calin GA, Ferracin M, Cimmino A, di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1768–1771.
Del Poeta G, Del Principe MI, Irno Consalvo MA, Maurillo L, Buccisano F, Venditti A et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005; 104: 2743–2752.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Treatment-related mortality and graft-versus-leukemia activity of allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.
Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Gruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukaemia with unmutated immunoglobulin variable heavy-chain gene status: implication of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602.
Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukaemia. J Clin Oncol 2005; 23: 3433–3438.
Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hagenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukaemia. J Clin Oncol 2005; 23: 3819–3829.
Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuittinen O et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005; 75: 199–205.
Acknowledgements
The study was supported by a grant from the Blood Disease Research Foundation in Finland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jantunen, E., Itälä, M., Siitonen, T. et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant 37, 1093–1098 (2006). https://doi.org/10.1038/sj.bmt.1705375
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705375
Keywords
This article is cited by
-
High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse
Medical Oncology (2013)
-
Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis
Bone Marrow Transplantation (2008)
-
Transplantation in chronic lymphocytic leukemia
Current Hematologic Malignancy Reports (2007)